Opioid-induced Constipation
📧 Sign up to get email alerts when something new happens for Opioid-induced Constipation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Prospective, Multicenter, Randomized, Parallel-controlled, Superiority Trial [Phase 3]
A Phase 3, prospective multicenter randomized trial evaluating treatment for opioid-induced constipation (OIC) that has not yet started recr…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Prospective, Multicenter, Randomized, Parallel-controlled, Superiority Trial [Phase 3]
This clinical trial update describes a prospective Phase 3 multicenter randomized study for opioid-induced constipation; recruitment has not…
-
CLINICAL_TRIALS withdrawal · 2026-03-23Clinical Trial Update: RELISTOR's Effects on Opioid-Induced Constipation
The RELISTOR trial evaluating its effects on opioid-induced constipation has been withdrawn.
-
EMA approval · 2026-01-19EMA Authorised: Relistor (methylnaltrexone bromide) — Bausch Health Ireland Limited
The EMA authorised Relistor (methylnaltrexone bromide) by Bausch Health Ireland Limited for opioid-induced constipation. The decision date w…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Experience
This entry reports an ongoing clinical trial evaluating naldemedine for opioid-induced constipation in cancer patients, focusing on clinical…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-12-10EMA Authorised: Rizmoic (naldemedine tosilate) — Shionogi B.V.
The European Medicines Agency has authorised Rizmoic (naldemedine tosilate) by Shionogi B.V. for constipation. It addresses opioid-induced c…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: Electroacupuncture for Opioid-Induced Constipation in Cancer Patients: A Randomized Clinical Trial [NA]
This entry reports the completion of a randomized clinical trial evaluating electroacupuncture for opioid-induced constipation in cancer pat…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Fiber-Enriched Enteral Nutrition and Opioid-Induced Constipation in the ICU
This clinical trial update reports the completion of a study evaluating fiber-enriched enteral nutrition for opioid-induced constipation in …
-
FDA approval · 2025-07-15FDA Approved: SYMPROIC — Supplemental Application (BioDelivery Sciences International Inc)
The FDA approved a supplemental application for Symproic (naldemedine) from BioDelivery Sciences International Inc, authorizing changes to t…
-
CLINICAL_TRIALS trial_result · 2025-07-15Clinical Trial Update: Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer [NA]
This clinical trial update reports the completion of a study evaluating electroacupuncture for opioid-induced constipation in cancer patient…
-
CLINICAL_TRIALS trial_result · 2025-06-26Clinical Trial Update: Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications [Phase 2]
Phase 2 results for BGP345A in opioid-induced constipation show safety signals and preliminary efficacy; the study has completed.
-
CLINICAL_TRIALS research · 2025-04-20Clinical Trial Update: Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids [Phase 1, Phase 2]
Phase 1/2 safety and pharmacokinetics study of naldemedine in pediatric participants receiving opioids for opioid-induced constipation; the …
-
EMA approval · 2025-04-11EMA Authorised: Moventig (naloxegol oxalate) — Grunenthal GmbH
EMA authorised Moventig (naloxegol oxalate) from Grunenthal GmbH for the treatment of constipation, including opioid-induced constipation. T…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: European Study of Opioid Induced Constipation
A European clinical trial investigating opioid-induced constipation has completed.
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
This clinical trial update describes an investigation into the risk of major adverse cardiovascular events with naldemedine and other opioid…
-
FDA approval · 2025-01-02FDA Approved: LUBIPROSTONE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original generic application for lubiprostone to treat chronic idiopathic constipation, opioid-induced …
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Prevention of Opioid-induced Constipation in Patients With Advanced Cancer [Phase 4]
Phase 4 clinical trial update on preventing opioid-induced constipation in patients with advanced cancer; recruitment is ongoing.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation [Phase 4]
Phase 4 trial comparing methylnaltrexone with naloxegol for opioid-induced constipation has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: Naloxegol Drug Utilization Post Authorisation Safety Study
A completed post-authorization safety study assessing real-world naloxegol utilization in patients with opioid-induced constipation.
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: Naloxegol Health Outcome Post Authorisation Safety Study
A post-authorization safety study of naloxegol for opioid-induced constipation sponsored by Kyowa Kirin Pharmaceutical Development Ltd has b…
-
CLINICAL_TRIALS research · 2024-06-17Clinical Trial Update: Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
A real-world observational study evaluating naloxegol for opioid-induced constipation in cancer pain patients has completed.
-
CLINICAL_TRIALS trial_result · 2024-06-17Clinical Trial Update: Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients [Phase 1]
Completed Phase I pharmacokinetics and safety study of Naloxegol in pediatric patients with opioid-induced constipation.
-
FDA approval · 2023-03-23FDA Approved: LUBIPROSTONE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original application for lubiprostone from Zydus Pharmaceuticals USA Inc., establishing a generic version of Lubiprostone. …
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: Colonic Motor Patterns in Healthy Volunteers [Phase 4]
Phase 4 clinical trial update evaluating colonic motor patterns in healthy volunteers for opioid-induced constipation.
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) [Phase 2]
Phase 2 trial update for TD-1211 in opioid-induced constipation completed.